Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHALLENGE: Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive NSCLC
NCT07264647Phase 2Recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Mar 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07264647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264647.